{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:52:07Z","timestamp":1794955927479,"version":"4.9.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is a rare, but potentially fatal, immune-mediated disease of the peripheral nerves and nerve roots that is usually triggered by infections. The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America. Diagnosis and management of GBS can be complicated as its clinical presentation and disease course are heterogeneous, and no international clinical guidelines are currently available. To support clinicians, especially in the context of an outbreak, we have developed a globally applicable guideline for the diagnosis and management of GBS. The guideline is based on current literature and expert consensus, and has a ten-step structure to facilitate its use in clinical practice. We first provide an introduction to the diagnostic criteria, clinical variants and differential diagnoses of GBS. The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae.<\/jats:p>","DOI":"10.1038\/s41582-019-0250-9","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T13:15:03Z","timestamp":1568985303000},"page":"671-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":814,"title":["Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-6926","authenticated-orcid":false,"given":"Sonja E.","family":"Leonhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Mandarakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-5796","authenticated-orcid":false,"given":"Francisco A. A.","family":"Gondim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0213-7102","authenticated-orcid":false,"given":"Kathleen","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L. B.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Cornblath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A. C.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Reisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Sejvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nortina","family":"Shahrizaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirugnanam","family":"Umapathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-8402","authenticated-orcid":false,"given":"Eppie M.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"Willison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"250_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J., Baughman, A. L., Wise, M. & Morgan, O. W. Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology 36, 123\u2013133 (2011).","journal-title":"Neuroepidemiology"},{"key":"250_CR2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ana.410030628","volume":"3","author":"AK Asbury","year":"1978","unstructured":"Asbury, A. K., Arnason, B. G. W., Karp, H. R. & McFarlin, D. E. Criteria for diagnosis of Guillain-Barr\u00e9 syndrome. Ann. Neurol. 3, 565\u2013566 (1978).","journal-title":"Ann. Neurol."},{"key":"250_CR3","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome. Ann. Neurol. 27, S21\u2013S24 (1990).","journal-title":"Ann. Neurol."},{"key":"250_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J. et al. Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599\u2013612 (2011).","journal-title":"Vaccine"},{"key":"250_CR5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"RD Hadden","year":"1998","unstructured":"Hadden, R. D. et al. Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Ann. Neurol. 44, 780\u2013788 (1998).","journal-title":"Ann. Neurol."},{"key":"250_CR6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barr\u00e9 syndrome. Lancet 388, 717\u2013727 (2016).","journal-title":"Lancet"},{"key":"250_CR7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","volume":"80","author":"B Van den Berg","year":"2013","unstructured":"Van den Berg, B., Bunschoten, C., van Doorn, P. A. & Jacobs, B. C. Mortality in Guillain-Barr\u00e9 syndrome. Neurology 80, 1650\u20131654 (2013).","journal-title":"Neurology"},{"key":"250_CR8","first-page":"4","volume":"58","author":"R Dominguez-Moreno","year":"2014","unstructured":"Dominguez-Moreno, R. et al. Mortalidad asociada al diagnostico de sindrome de Guillain-Barr\u00e9 en adultos ingresados en instituciones del sistema sanitario Mexicano [mortality associated with a diagnosis of Guillain-Barr\u00e9 syndrome in adults of Mexican health institutions]. Rev. Neurol. 58, 4\u201310 (2014).","journal-title":"Rev. Neurol."},{"key":"250_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0404.2011.01503.x","volume":"125","author":"ME Dourado","year":"2012","unstructured":"Dourado, M. E., Felix, R. H., da Silva, W. K., Queiroz, J. W. & Jeronimo, S. M. Clinical characteristics of Guillain-Barr\u00e9 syndrome in a tropical country: a Brazilian experience. Acta Neurol. Scand. 125, 47\u201353 (2012).","journal-title":"Acta Neurol. Scand."},{"key":"250_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"C Fokke","year":"2014","unstructured":"Fokke, C. et al. Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria. Brain 137, 33\u201343 (2014).","journal-title":"Brain"},{"key":"250_CR11","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","volume":"141","author":"AY Doets","year":"2018","unstructured":"Doets, A. Y. et al. Regional variation of Guillain-Barr\u00e9 syndrome. Brain 141, 2866\u20132877 (2018).","journal-title":"Brain"},{"key":"250_CR12","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts, L., Drenthen, J., Jacobs, B. C., van Doorn, P. A. & Dutch Guillain-Barr\u00e9 syndrome Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barr\u00e9 syndrome: a prospective study. Neurology 74, 1680\u20131686 (2010).","journal-title":"Neurology"},{"key":"250_CR13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","volume":"54","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P. & van der Meche, F. G. Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange. J.\u00a0Neurol. Neurosurg. Psychiatry 54, 957\u2013960 (1991).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1529-8027.2009.00243.x","volume":"14","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K., Bos-Eyssen, M. E., Blomkwist-Markens, P. H. & van Doorn, P. A. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J. Peripher. Nerv. Syst. 14, 310\u2013315 (2009).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR15","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","volume":"37","author":"N Principi","year":"2019","unstructured":"Principi, N. & Esposito, S. Vaccine-preventable diseases, vaccines and Guillain-Barr\u00e9 syndrome. Vaccine 37, 5544\u20135550 (2019).","journal-title":"Vaccine"},{"key":"250_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1473-3099(01)00019-6","volume":"1","author":"N Yuki","year":"2001","unstructured":"Yuki, N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. 1, 29\u201337 (2001).","journal-title":"Lancet Infect. Dis."},{"key":"250_CR17","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000501","volume":"5","author":"K Yoshikawa","year":"2018","unstructured":"Yoshikawa, K. et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol. Neuroimmunol. Neuroinflamm. 5, e501 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"250_CR18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs, B. C. et al. The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study. Neurology 51, 1110\u20131115 (1998).","journal-title":"Neurology"},{"key":"250_CR19","unstructured":"World Health Organization. Zika Situation Report 5 February 2016 https:\/\/www.who.int\/emergencies\/zika-virus\/situation-report\/5-february-2016\/en\/ (2016)."},{"key":"250_CR20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","volume":"387","author":"VM Cao-Lormeau","year":"2016","unstructured":"Cao-Lormeau, V. M. et al. Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531\u20131539 (2016).","journal-title":"Lancet"},{"key":"250_CR21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","volume":"375","author":"B Parra","year":"2016","unstructured":"Parra, B. et al. Guillain-Barr\u00e9 syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513\u20131523 (2016).","journal-title":"N. Engl. J. Med."},{"key":"250_CR22","doi-asserted-by":"crossref","first-page":"1398485","DOI":"10.1080\/16549716.2017.1398485","volume":"10","author":"A Wilder-Smith","year":"2017","unstructured":"Wilder-Smith, A. et al. ZikaPLAN: Zika preparedness Latin American Network. Glob. Health Action 10, 1398485 (2017).","journal-title":"Glob. Health Action"},{"key":"250_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jns.12209","volume":"22","author":"BC Jacobs","year":"2017","unstructured":"Jacobs, B. C. et al. International Guillain-Barre syndrome outcome study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 22, 68\u201376 (2017).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR24","unstructured":"Ropper, A. H., Wijdickr, E. F. M. & Truax, B. T. in Guillain-Barr\u00e9 Syndrome Ch. 12 (ed: Plum, F.) 155\u2013160 (F.A. Davis Company, 1991)."},{"key":"250_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B Van den Berg","year":"2014","unstructured":"Van den Berg, B. et al. Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469\u2013482 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"250_CR26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.0b013e3181f88345","volume":"75","author":"L Ruts","year":"2010","unstructured":"Ruts, L. et al. Pain in Guillain-Barr\u00e9 syndrome: a long-term follow-up study. Neurology 75, 1439\u20131447 (2010).","journal-title":"Neurology"},{"key":"250_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-2007-981686","volume":"38","author":"R Korinthenberg","year":"2007","unstructured":"Korinthenberg, R., Schessl, J. & Kirschner, J. Clinical presentation and course of childhood Guillain-Barr\u00e9 syndrome: a prospective multicentre study. Neuropediatrics 38, 10\u201317 (2007).","journal-title":"Neuropediatrics"},{"key":"250_CR28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","volume":"76","author":"J Roodbol","year":"2011","unstructured":"Roodbol, J. et al. Recognizing Guillain-Barr\u00e9 syndrome in preschool children. Neurology 76, 807\u2013810 (2011).","journal-title":"Neurology"},{"key":"250_CR29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00415-011-6330-4","volume":"259","author":"N Yuki","year":"2012","unstructured":"Yuki, N. et al. Guillain-Barr\u00e9 syndrome associated with normal or exaggerated tendon reflexes. J. Neurol. 259, 1181\u20131190 (2012).","journal-title":"J. Neurol."},{"key":"250_CR30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-008-0775-0","volume":"255","author":"M Ito","year":"2008","unstructured":"Ito, M. et al. Bickerstaff\u2019s brainstem encephalitis and fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J. Neurol. 255, 674\u2013682 (2008).","journal-title":"J. Neurol."},{"key":"250_CR31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley, B. R. et al. Guillain\u2013Barr\u00e9 and Miller Fisher syndromes\u2014new diagnostic classification. Nat. Rev. Neurol. 10, 537\u2013544 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"250_CR32","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/ene.12983","volume":"23","author":"Y Sekiguchi","year":"2016","unstructured":"Sekiguchi, Y. et al. How often and when fisher syndrome is overlapped by Guillain-Barr\u00e9 syndrome or Bickerstaff brainstem encephalitis? Eur. J. Neurol. 23, 1058\u20131063 (2016).","journal-title":"Eur. J. Neurol."},{"key":"250_CR33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mus.22298","volume":"45","author":"A Uncini","year":"2012","unstructured":"Uncini, A. & Yuki, N. Sensory Guillain-Barr\u00e9 syndrome and related disorders: an attempt at systematization. Muscle Nerve 45, 464\u2013470 (2012).","journal-title":"Muscle Nerve"},{"key":"250_CR34","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/awg233","volume":"126","author":"M Odaka","year":"2003","unstructured":"Odaka, M. et al. Bickerstaff\u2019s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barr\u00e9 syndrome. Brain 126, 2279\u20132290 (2003).","journal-title":"Brain"},{"key":"250_CR35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/jnnp.2010.222836","volume":"82","author":"M Ito","year":"2011","unstructured":"Ito, M., Matsuno, K., Sakumoto, Y., Hirata, K. & Yuki, N. Ataxic Guillain-Barr\u00e9 syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry 82, 294\u2013299 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391\u2013404 (2016).","journal-title":"Lancet Neurol."},{"key":"250_CR37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","volume":"82","author":"B Van den Berg","year":"2014","unstructured":"Van den Berg, B. et al. Guillain-Barr\u00e9 syndrome associated with preceding hepatitis E virus infection. Neurology 82, 491\u2013497 (2014).","journal-title":"Neurology"},{"key":"250_CR38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","volume":"58","author":"C Vellozzi","year":"2014","unstructured":"Vellozzi, C., Iqbal, S. & Broder, K. Guillain-Barr\u00e9 syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin. Infect. Dis. 58, 1149\u20131155 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"250_CR39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/WNL.41.6.812","volume":"41","author":"CA Thornton","year":"1991","unstructured":"Thornton, C. A., Latif, A. S. & Emmanuel, J. C. Guillain-Barr\u00e9 syndrome associated with human immunodeficiency virus infection in Zimbabwe. Neurology 41, 812\u2013815 (1991).","journal-title":"Neurology"},{"key":"250_CR40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10096-018-3199-5","volume":"37","author":"B Islam","year":"2018","unstructured":"Islam, B. et al. Guillain-Barr\u00e9 syndrome following varicella-zoster virus infection. Eur. J. Clin. Microbiol. Infect. Dis. 37, 511\u2013518 (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"250_CR41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1474-4422(13)70150-9","volume":"12","author":"FJ Carod-Artal","year":"2013","unstructured":"Carod-Artal, F. J., Wichmann, O., Farrar, J. & Gascon, J. Neurological complications of dengue virus infection. Lancet Neurol. 12, 906\u2013919 (2013).","journal-title":"Lancet Neurol."},{"key":"250_CR42","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1212\/01.wnl.0000277267.07220.88","volume":"69","author":"AC Wielanek","year":"2007","unstructured":"Wielanek, A. C., Monredon, J. D., Amrani, M. E., Roger, J. C. & Serveaux, J. P. Guillain-Barr\u00e9 syndrome complicating a Chikungunya virus infection. Neurology 69, 2105\u20132107 (2007).","journal-title":"Neurology"},{"key":"250_CR43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.410210107","volume":"21","author":"DR Cornblath","year":"1987","unstructured":"Cornblath, D. R., McArthur, J. C., Kennedy, P. G., Witte, A. S. & Griffin, J. W. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann. Neurol. 21, 32\u201340 (1987).","journal-title":"Ann. Neurol."},{"key":"250_CR44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger, L. B. et al. Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977. Am. J. Epidemiol. 110, 105\u2013123 (1979).","journal-title":"Am. J. Epidemiol."},{"key":"250_CR45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","volume":"39","author":"DR Burwen","year":"2010","unstructured":"Burwen, D. R. et al. Evaluation of Guillain-Barr\u00e9 syndrome among recipients of influenza vaccine in 2000 and 2001. Am. J. Prev. Med. 39, 296\u2013304 (2010).","journal-title":"Am. J. Prev. Med."},{"key":"250_CR46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1982.03330060038030","volume":"248","author":"JE Kaplan","year":"1982","unstructured":"Kaplan, J. E., Katona, P., Hurwitz, E. S. & Schonberger, L. B. Guillain-Barr\u00e9 syndrome in the United States, 1979\u20131980 and 1980\u20131981: lack of an association with influenza vaccination. JAMA 248, 698\u2013700 (1982).","journal-title":"JAMA"},{"key":"250_CR47","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","volume":"339","author":"T Lasky","year":"1998","unstructured":"Lasky, T. et al. The Guillain-Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines. N.\u00a0Engl. J. Med. 339, 1797\u20131802 (1998).","journal-title":"N. Engl. J. Med."},{"key":"250_CR48","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","volume":"166","author":"DN Juurlink","year":"2006","unstructured":"Juurlink, D. N. et al. Guillain-Barr\u00e9 syndrome after influenza vaccination in adults: a population-based study. Arch. Intern. Med. 166, 2217\u20132221 (2006).","journal-title":"Arch. Intern. Med."},{"key":"250_CR49","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao, J. C., Brickshawana, A. & Liewluck, T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr. Neurol. Neurosci. Rep. 18, 63 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"250_CR50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jns.2017.02.024","volume":"375","author":"FL Hiew","year":"2017","unstructured":"Hiew, F. L. & Rajabally, Y. A. Malignancy in Guillain-Barr\u00e9 syndrome: a twelve-year single-center study. J.\u00a0Neurol. Sci. 375, 275\u2013278 (2017).","journal-title":"J. Neurol. Sci."},{"key":"250_CR51","doi-asserted-by":"crossref","first-page":"e1220","DOI":"10.1212\/WNL.0000000000006246","volume":"91","author":"J Rudant","year":"2018","unstructured":"Rudant, J. et al. Surgery and risk of Guillain-Barr\u00e9 syndrome: a French nationwide epidemiologic study. Neurology 91, e1220\u2013e1227 (2018).","journal-title":"Neurology"},{"key":"250_CR52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho, T. W. et al. Guillain-Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118, 597\u2013605 (1995).","journal-title":"Brain"},{"key":"250_CR53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2005.07.009","volume":"239","author":"ML Kuijf","year":"2005","unstructured":"Kuijf, M. L. et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J. Neurol. Sci. 239, 37\u201344 (2005).","journal-title":"J. Neurol. Sci."},{"key":"250_CR54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2016.07.021","volume":"298","author":"A Uchibori","year":"2016","unstructured":"Uchibori, A., Gyohda, A. & Chiba, A. Ca2+-dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J. Neuroimmunol. 298, 172\u2013177 (2016).","journal-title":"J. Neuroimmunol."},{"key":"250_CR55","first-page":"1462","volume":"40","author":"G Guillain","year":"1916","unstructured":"Guillain, G. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquode cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux [radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes]. Bell. Mem. Soc. Med. Paris 40, 1462\u20131470 (1916).","journal-title":"Bell. Mem. Soc. Med. Paris"},{"key":"250_CR56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jns.12104","volume":"20","author":"AH Wong","year":"2015","unstructured":"Wong, A. H. et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barr\u00e9 and Miller Fisher syndromes. J. Peripher. Nerv. Syst. 20, 47\u201351 (2015).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR57","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.clinph.2004.05.009","volume":"115","author":"S Vucic","year":"2004","unstructured":"Vucic, S., Cairns, K. D., Black, K. R., Chong, P. S. & Cros, D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin. Neurophysiol. 115, 2329\u20132335 (2004).","journal-title":"Clin. Neurophysiol."},{"key":"250_CR58","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/jnnp.59.5.482","volume":"59","author":"J Meulstee","year":"1995","unstructured":"Meulstee, J., van der Meche, F. & Dutch Guillain-Barr\u00e9 Study Group. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 59, 482\u2013486 (1995).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00415-016-8204-2","volume":"264","author":"J Berciano","year":"2017","unstructured":"Berciano, J. et al. Proximal nerve lesions in early Guillain-Barr\u00e9 syndrome: implications for pathogenesis and disease classification. J. Neurol. 264, 221\u2013236 (2017).","journal-title":"J. Neurol."},{"key":"250_CR60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clinph.2016.11.009","volume":"128","author":"S Kuwabara","year":"2017","unstructured":"Kuwabara, S., Sekiguchi, Y. & Misawa, S. Electrophysiology in Fisher syndrome. Clin. Neurophysiol. 128, 215\u2013219 (2017).","journal-title":"Clin. Neurophysiol."},{"key":"250_CR61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","volume":"86","author":"YA Rajabally","year":"2015","unstructured":"Rajabally, Y. A., Durand, M. C., Mitchell, J., Orlikowski, D. & Nicolas, G. Electrophysiological diagnosis of Guillain-Barr\u00e9 syndrome subtype: could a single study suffice? J. Neurol. Neurosurg. Psychiatry 86, 115\u2013119 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR62","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1016\/j.clinph.2018.09.025","volume":"129","author":"A Uncini","year":"2018","unstructured":"Uncini, A. & Kuwabara, S. The electrodiagnosis of Guillain-Barr\u00e9 syndrome subtypes: where do we stand? Clin. Neurophysiol. 129, 2586\u20132593 (2018).","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"250_CR63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mus.26056","volume":"58","author":"Peter Y. K. Van den Bergh","year":"2018","unstructured":"Van den Bergh, P. Y. K. et al. Guillain-Barr\u00e9 syndrome subtype diagnosis: a prospective multicentric European study. Muscle Nerve 58, 23-28 (2018).","journal-title":"Muscle & Nerve"},{"key":"250_CR64","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinph.2012.01.025","volume":"123","author":"A Uncini","year":"2012","unstructured":"Uncini, A. & Kuwabara, S. Electrodiagnostic criteria for Guillain-Barr\u00e9 syndrome: a critical revision and the need for an update. Clin. Neurophysiol. 123, 1487\u20131495 (2012).","journal-title":"Clin. Neurophysiol."},{"key":"250_CR65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.47.3.813","volume":"47","author":"KC Gorson","year":"1996","unstructured":"Gorson, K. C., Ropper, A. H., Muriello, M. A. & Blair, R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barr\u00e9 syndrome. Neurology 47, 813\u2013817 (1996).","journal-title":"Neurology"},{"key":"250_CR66","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00381-010-1197-8","volume":"26","author":"A Yikilmaz","year":"2010","unstructured":"Yikilmaz, A. et al. Magnetic resonance imaging of childhood Guillain-Barr\u00e9 syndrome. Childs Nerv. Syst. 26, 1103\u20131108 (2010).","journal-title":"Childs Nerv. Syst."},{"key":"250_CR67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamapediatrics.2018.4890","volume":"173","author":"MJ Elrick","year":"2018","unstructured":"Elrick, M. J. et al. Clinical subpopulations in a sample of North American children diagnosed with acute flaccid myelitis, 2012\u20132016. JAMA Pediatr. 173, 134\u2013139 (2018).","journal-title":"JAMA Pediatr."},{"key":"250_CR68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamapediatrics.2018.4896","volume":"173","author":"SE Hopkins","year":"2018","unstructured":"Hopkins, S. E., Elrick, M. J. & Messacar, K. Acute flaccid myelitis\u2014keys to diagnosis, questions about treatment, and future directions. JAMA Pediatr. 173, 117\u2013118 (2018).","journal-title":"JAMA Pediatr."},{"key":"250_CR69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3174\/ajnr.A4188","volume":"36","author":"JA Maloney","year":"2015","unstructured":"Maloney, J. A. et al. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am. J. Neuroradiol. 36, 245\u2013250 (2015).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"250_CR70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.clinph.2014.06.051","volume":"126","author":"E Gallardo","year":"2015","unstructured":"Gallardo, E. et al. Spinal nerve involvement in early Guillain-Barr\u00e9 syndrome: a clinico-electrophysiological, ultrasonographic and pathological study. Clin. Neurophysiol. 126, 810\u2013819 (2015).","journal-title":"Clin. Neurophysiol."},{"key":"250_CR71","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.clinph.2015.06.030","volume":"127","author":"SNO Razali","year":"2016","unstructured":"Razali, S. N. O. et al. Serial peripheral nerve ultrasound in Guillain-Barr\u00e9 syndrome. Clin. Neurophysiol. 127, 1652\u20131656 (2016).","journal-title":"Clin. Neurophysiol."},{"key":"250_CR72","unstructured":"Vereninging Spierziekten Nederland, Nederlandse Vereniging voor Neurologie & Nederlandse Vereniging van Revalidatieartsen [Dutch Association of Muscular Diseases & Dutch Society of Rehabilitation Specialists]. in Multidisciplinaire richtlijn Guillain-Barr\u00e9 syndroom [Multidisciplinary guideline Guillain-Barr\u00e9 syndrome] https:\/\/www.spierziekten.nl\/fileadmin\/user_upload\/VSN\/documenten\/Hulpverleners_overig\/R030-RichtlijnGBSherdruk2011metbijlagen.pdf (2011)."},{"key":"250_CR73","first-page":"1016","volume":"51","author":"S Mehta","year":"2006","unstructured":"Mehta, S. Neuromuscular disease causing acute respiratory failure. Respir. Care 51, 1016\u20131021 (2006).","journal-title":"Respir. Care"},{"key":"250_CR74","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","volume":"67","author":"C Walgaard","year":"2010","unstructured":"Walgaard, C. et al. Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome. Ann. Neurol. 67, 781\u2013787 (2010).","journal-title":"Ann. Neurol."},{"key":"250_CR75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-016-0311-5","volume":"26","author":"C Walgaard","year":"2017","unstructured":"Walgaard, C. et al. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain\u2013Barr\u00e9 syndrome. Neurocrit. Care 26, 6\u201313 (2017).","journal-title":"Neurocrit. Care"},{"key":"250_CR76","first-page":"CD002063","volume":"9","author":"RA Hughes","year":"2014","unstructured":"Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. 9, CD002063 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"250_CR77","first-page":"CD001798","volume":"2","author":"S Chevret","year":"2017","unstructured":"Chevret, S. Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. 2, CD001798 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"250_CR78","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"R Korinthenberg","year":"2005","unstructured":"Korinthenberg, R., Schessl, J., Kirschner, J. & Monting, J. S. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial. Pediatrics 116, 8\u201314 (2005).","journal-title":"Pediatrics"},{"key":"250_CR79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","volume":"41","author":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1997","unstructured":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome. Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome. Ann. Neurol. 41, 298\u2013306 (1997).","journal-title":"Ann. Neurol."},{"key":"250_CR80","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","volume":"88","author":"C Verboon","year":"2017","unstructured":"Verboon, C., van Doorn, P. A. & Jacobs, B. C. Treatment dilemmas in Guillain-Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 88, 346\u2013352 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR81","first-page":"CD001798","volume":"7","author":"JC Raphael","year":"2012","unstructured":"Raphael, J. C., Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. 7, CD001798 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"250_CR82","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes, R. A. et al. Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review. Brain 130, 2245\u20132257 (2007).","journal-title":"Brain"},{"key":"250_CR83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R Van Koningsveld","year":"2004","unstructured":"Van Koningsveld, R. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial. Lancet 363, 192\u2013196 (2004).","journal-title":"Lancet"},{"key":"250_CR84","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-017-0185-0","volume":"3","author":"MB Islam","year":"2017","unstructured":"Islam, M. B. et al. Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource poor settings: a safety and feasibility study. Pilot Feasibility Stud. 3, 40 (2017).","journal-title":"Pilot Feasibility Stud."},{"key":"250_CR85","first-page":"CD004761","volume":"1","author":"JR Overell","year":"2007","unstructured":"Overell, J. R., Hseih, S.-T., Odaka, M., Yuki, N. & Willison, H. J. Treatment for Fisher syndrome, Bickerstaff\u2019s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev. 1, CD004761 (2007).","journal-title":"Cochrane Database Syst. Rev."},{"key":"250_CR86","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","volume":"93","author":"C Verboon","year":"2019","unstructured":"Verboon, C. et al. Current treatment practice of Guillain-Barr\u00e9 syndrome. Neurology 93, e59\u2013e76 (2019).","journal-title":"Neurology"},{"key":"250_CR87","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejogrb.2016.03.031","volume":"201","author":"T Tomimatsu","year":"2016","unstructured":"Tomimatsu, T. et al. Guillain-Barr\u00e9 syndrome after trivalent influenza vaccination during pregnancy. Eur.\u00a0J. Obstet. Gynecol. Reprod. Biol. 201, 225\u2013226 (2016).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"250_CR88","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/AOG.0000000000001716","volume":"128","author":"LD Pacheco","year":"2016","unstructured":"Pacheco, L. D., Saad, A. F., Hankins, G. D., Chiosi, G. & Saade, G. Guillain-Barr\u00e9 syndrome in pregnancy. Obstet. Gynecol. 128, 1105\u20131110 (2016).","journal-title":"Obstet. Gynecol."},{"key":"250_CR89","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1067\/mai.2001.117821","volume":"108","author":"DW Branch","year":"2001","unstructured":"Branch, D. W., Porter, T. F., Paidas, M. J., Belfort, M. A. & Gonik, B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J.\u00a0Allergy Clin. Immunol. 108, S133\u2013S138 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"250_CR90","volume":"15","author":"MA El-Bayoumi","year":"2011","unstructured":"El-Bayoumi, M. A. et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain-Barr\u00e9 syndrome: a randomized study. Crit. Care 15, R164 (2011).","journal-title":"Crit. Care"},{"key":"250_CR91","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","volume":"47","author":"B Michon","year":"2007","unstructured":"Michon, B. et al. Complications of apheresis in children. Transfusion 47, 1837\u20131842 (2007).","journal-title":"Transfusion"},{"key":"250_CR92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcrc.2013.10.026","volume":"29","author":"MA Kannan Kanikannan","year":"2014","unstructured":"Kannan Kanikannan, M. A. et al. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J. Crit. Care 29, 219\u2013223 (2014).","journal-title":"J. Crit. Care"},{"key":"250_CR93","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archneur.58.6.893","volume":"58","author":"ND Lawn","year":"2001","unstructured":"Lawn, N. D., Fletcher, D. D., Henderson, R. D., Wolter, T. D. & Wijdicks, E. F. Anticipating mechanical ventilation in Guillain-Barr\u00e9 syndrome. Arch. Neurol. 58, 893\u2013898 (2001).","journal-title":"Arch. Neurol."},{"key":"250_CR94","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"312","author":"RAC Hughes","year":"1978","unstructured":"Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial of prednisolone in acute polyneuropathy. Lancet 312, 750\u2013753 (1978).","journal-title":"Lancet"},{"key":"250_CR95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2007.08.005","volume":"264","author":"R Dhar","year":"2008","unstructured":"Dhar, R., Stitt, L. & Hahn, A. F. The morbidity and outcome of patients with Guillain-Barr\u00e9 syndrome admitted to the intensive care unit. J. Neurol. Sci. 264, 121\u2013128 (2008).","journal-title":"J. Neurol. Sci."},{"key":"250_CR96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","volume":"12","author":"M Oczko-Walker","year":"2010","unstructured":"Oczko-Walker, M., Manousakis, G., Wang, S., Malter, J. S. & Waclawik, A. J. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency. J. Clin. Neuromuscul. Dis. 12, 55\u201361 (2010).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"250_CR97","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","volume":"350","author":"P Farcas","year":"1997","unstructured":"Farcas, P., Avnun, L., Frisher, S., Herishanu, Y. O. & Wirguin, I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome. Lancet 350, 1747 (1997).","journal-title":"Lancet"},{"key":"250_CR98","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jns.12286","volume":"23","author":"C Walgaard","year":"2018","unstructured":"Walgaard, C. et al. Second IVIg course in Guillain-Barr\u00e9 syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J. Peripher. Nerv. Syst. 23, 210\u2013215 (2018).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR99","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/jnnp-2018-317968","volume":"89","author":"B Van den Berg","year":"2018","unstructured":"Van den Berg, B., Storm, E. F., Garssen, M. J. P., Blomkwist-Markens, P. H. & Jacobs, B. C. Clinical outcome of Guillain-Barr\u00e9 syndrome after prolonged mechanical ventilation. J. Neurol. Neurosurg. Psychiatry 89, 949\u2013954 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR100","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","volume":"76","author":"C Walgaard","year":"2011","unstructured":"Walgaard, C. et al. Early recognition of poor prognosis in Guillain-Barr\u00e9 syndrome. Neurology 76, 968\u2013975 (2011).","journal-title":"Neurology"},{"key":"250_CR101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0404.2010.01366.x","volume":"123","author":"A Soysal","year":"2011","unstructured":"Soysal, A. et al. Clinico-electrophysiological findings and prognosis of Guillain-Barr\u00e9 syndrome\u201410 years\u2019 experience. Acta Neurol. Scand. 123, 181\u2013186 (2011).","journal-title":"Acta Neurol. Scand."},{"key":"250_CR102","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","volume":"253","author":"A Bersano","year":"2006","unstructured":"Bersano, A. et al. Long term disability and social status change after Guillain-Barr\u00e9 syndrome. J.\u00a0Neurol. 253, 214\u2013218 (2006).","journal-title":"J. Neurol."},{"key":"250_CR103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jns.2012.02.026","volume":"317","author":"A Forsberg","year":"2012","unstructured":"Forsberg, A., Press, R. & Holmqvist, L. W. Residual disability 10 years after falling ill in Guillain-Barr\u00e9 syndrome: a prospective follow-up study. J. Neurol. Sci. 317, 74\u201379 (2012).","journal-title":"J. Neurol. Sci."},{"key":"250_CR104","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.62.8.1194","volume":"62","author":"RA Hughes","year":"2005","unstructured":"Hughes, R. A. et al. Supportive care for patients with Guillain-Barr\u00e9 syndrome. Arch. Neurol. 62, 1194\u20131198 (2005).","journal-title":"Arch. Neurol."},{"key":"250_CR105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.physio.2009.04.001","volume":"95","author":"I Davidson","year":"2009","unstructured":"Davidson, I., Wilson, C., Walton, T. & Brissenden, S. Physiotherapy and Guillain-Barr\u00e9 syndrome: results of a national survey. Physiotherapy 95, 157\u2013163 (2009).","journal-title":"Physiotherapy"},{"key":"250_CR106","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3138\/ptc.2015-58","volume":"68","author":"N Simatos Arsenault","year":"2016","unstructured":"Simatos Arsenault, N., Vincent, P.-O., Yu, B. H. S., Bastien, R. & Sweeney, A. Influence of exercise on patients with Guillain-Barr\u00e9 syndrome: a systematic review. Physiother. Can. 68, 367\u2013376 (2016).","journal-title":"Physiother. Can."},{"key":"250_CR107","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00415-006-0163-6","volume":"253","author":"MP Garssen","year":"2006","unstructured":"Garssen, M. P., Van Koningsveld, R. & Van Doorn, P. A. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barr\u00e9 syndrome. J.\u00a0Neurol. 253, 1143\u20131146 (2006).","journal-title":"J. Neurol."},{"key":"250_CR108","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/WNL.53.8.1648","volume":"53","author":"IS Merkies","year":"1999","unstructured":"Merkies, I. S. et al. Fatigue in immune-mediated polyneuropathies. Neurology 53, 1648\u20131654 (1999).","journal-title":"Neurology"},{"key":"250_CR109","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1212\/01.WNL.0000148589.87107.9C","volume":"63","author":"MPJ Garssen","year":"2004","unstructured":"Garssen, M. P. J. et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barr\u00e9 syndrome and CIDP. Neurology 63, 2393\u20132395 (2004).","journal-title":"Neurology"},{"key":"250_CR110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mus.21536","volume":"41","author":"RA Bernsen","year":"2010","unstructured":"Bernsen, R. A., de Jager, A. E., Kuijer, W., van der Meche, F. G. & Suurmeijer, T. P. Psychosocial dysfunction in the first year after Guillain-Barr\u00e9 syndrome. Muscle Nerve 41, 533\u2013539 (2010).","journal-title":"Muscle Nerve"},{"key":"250_CR111","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.expneurol.2017.02.010","volume":"291","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barr\u00e9 syndrome. Exp. Neurol. 291, 134\u2013140 (2017).","journal-title":"Exp. Neurol."},{"key":"250_CR112","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa, S. et al. Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 17, 519\u2013529 (2018).","journal-title":"Lancet Neurol."},{"key":"250_CR113","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/practneurol-2014-000937","volume":"15","author":"BR Wakerley","year":"2015","unstructured":"Wakerley, B. R. & Yuki, N. Mimics and chameleons in Guillain-Barr\u00e9 and Miller Fisher syndromes. Pract. Neurol. 15, 90\u201399 (2015).","journal-title":"Pract. Neurol."},{"key":"250_CR114","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2016.08.002","volume":"369","author":"BR Wakerley","year":"2016","unstructured":"Wakerley, B. R. et al. Clinical classification of 103 Japanese patients with Guillain-Barre syndrome. J.\u00a0Neurol. Sci. 369, 43\u201347 (2016).","journal-title":"J. Neurol. Sci."},{"key":"250_CR115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clineuro.2017.05.006","volume":"158","author":"FL Hiew","year":"2017","unstructured":"Hiew, F. L., Ramlan, R., Viswanathan, S. & Puvanarajah, S. Guillain-Barr\u00e9 syndrome, variants & forms fruste: reclassification with new criteria. Clin.\u00a0Neurol. Neurosurg. 158, 114\u2013118 (2017).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"250_CR116","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jns5.12045","volume":"18","author":"S Blum","year":"2013","unstructured":"Blum, S., Reddel, S., Spies, J. & McCombe, P. Clinical features of patients with Guillain-Barr\u00e9 syndrome at seven hospitals on the East Coast of Australia. J.\u00a0Peripher. Nerv. Syst. 18, 316\u2013320 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR117","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jns.12096","volume":"19","author":"S Peric","year":"2014","unstructured":"Peric, S. et al. Clinical and epidemiological features of Guillain-Barr\u00e9 syndrome in the western Balkans. J.\u00a0Peripher. Nerv. Syst. 19, 317\u2013321 (2014).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"250_CR118","volume":"10","author":"G Zhang","year":"2015","unstructured":"Zhang, G. et al. Subtypes and prognosis of Guillain-Barr\u00e9 syndrome in Southwest China. PLOS ONE 10, e0133520 (2015).","journal-title":"PLOS ONE"},{"key":"250_CR119","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/jnnp-2013-306509","volume":"86","author":"Y Mitsui","year":"2015","unstructured":"Mitsui, Y. et al. A multicentre prospective study of Guillain-Barr\u00e9 syndrome in Japan: a focus on the incidence of subtypes. J. Neurol. Neurosurg. Psychiatry 86, 110\u2013114 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"250_CR120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jns.12215","volume":"22","author":"T Ishaque","year":"2017","unstructured":"Ishaque, T. et al. High mortality from Guillain-Barr\u00e9 syndrome in Bangladesh. J. Peripher. Nerv. Syst. 22, 121\u2013126 (2017).","journal-title":"J. Peripher. Nerv. Syst."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0250-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:48:52Z","timestamp":1721753332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-019-0250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":120,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1038\/s41582-019-0250-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736646353.793572130","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"assertion":[{"value":"5 August 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C.J. has received funding from Annexon Biosciences, Baxter, CSL Behring, Hansa Biopharma and Grifols. D.R.C. has received consultancy honoraria from Annexon Biosciences, argenx, Biotest Pharmaceuticals, Cigna Health Management, CSL Behring, DP Clinical, Grifols, Hansa Biopharma, New Enterprise Associates, Octapharma, Pharnext SAS, Polyneuron Pharmaceuticals, Seattle Genetics, Stealth BioTherapeutics, and Syntimmune. D.R.C is also on a data safety monitoring board for Pfizer, Sanofi, Alnylam Pharmaceuticals, PledPharma, and Momenta Pharma. Johns Hopkins University has licensed technology to AstraZeneca Pharmaceuticals, Genentech, Levicept, Seattle Genetics, Merrimack Pharmaceuticals, Levicept and Disarm Therapeutics, for which D.R.C. receives royalties. P.A.v.D. received a grant from Sanquin Blood supply for the SID-GBS randomized controlled trial, and a grant from Grifols to conduct the I-SID GBS study. R.A.C.H. has received consultancy honoraria from Laboratoire Francais du Fractionnement et des Biotechnologies (LFB S.A.). S.K. has received speaker honoraria from Teijin Pharma, Nihon Pharmaceutical and Japan Blood Products Organization, and research support from Nihon Pharmaceutical and Japan Blood Products Organization. R.R. is supported by a grant from CSL Behring. N.S. receives research support from Hovid Berhad. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}